Critical Innovations is developing this patented technology through two separate US Army Medical Research & Development Command (USAMRDC..
Critical Innovations is developing this patent-pending technology via funding from the US Army Medical Materiel Development Activity
Recipient of the MTEC 2020 Prototype of the Year Award, this program is funded by the U.S. Army Medical Materiel Development Activity (USAMMDA)..
Under a previous Phase I SBIR award and under current Phase II SBIR funding from the US Army, Critical Innovations is currently developing Succor™...
Previously funded under a Defense Health Agency (DHA) Direct-to-Phase II SBIR award, and currently funded under both DHA Phase IIE...
Funded by the JPC-2/Military Infectious Diseases Research Program through an Other Transaction Agreement with Military Technology...
- CAUTION -
All medical technologies listed on this page are INVESTIGATIONAL and NOT AVAILABLE FOR COMMERCIAL SALE. These statements have NOT been evaluated by the Food and Drug Administration and these technologies are NOT currently approved for human use.
CD010 Rev.K 2023-09-15